trending Market Intelligence /marketintelligence/en/news-insights/trending/s30UbjeWYZD-TirCZG_6XA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

S&P upgrades Abbott's long-term issuer credit rating

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

S&P upgrades Abbott's long-term issuer credit rating

S&P Global Ratings upgraded its long-term issuer credit rating for Abbott Laboratories to a BBB+ from BBB, saying that the company "significantly outperformed" the rating agency's base-case projections for EBITDA growth and debt repayment.

The medical device maker improved its 2018 leveraging ratio to 2.5x due to strong EBITDA margin expansion and $8.3 billion of debt repayment in 2018, according to the rating agency.

S&P Global Ratings said it expects further leverage reduction for Abbott, projecting a reduction to 2.2x by the end of 2019.

The agency's outlook on the company is positive, reflecting the expectations for further leverage improvement and the potential of a higher future rating if the company's performance remains strong.

Abbott's debt reduction comes shortly after the company purchase of St. Jude Medical Inc. and Alere Inc. in 2017, according to the ratings release.

The rating agency also changed Abbott's unsecured debt rating from BBB to BBB+.

This article was published by S&P Global Market Intelligence and not by S&P Global Ratings, which is a separately managed division of S&P Global.